This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content

Menu

Close

HomeUncontrolled UCWhy Patients SettlePrevalence & ImpactDisease NavigatorResources

Menu

Close

HomeUncontrolled UCWhy Patients SettlePrevalence & ImpactDisease NavigatorResources
Understanding UC

UC is the most common type of inflammatory bowel disease (IBD).1 IBD is the definition of a group of diseases that cause long-term inflammation in the digestive system, which can lead to considerable damage on the digestive organs and make it harder for them to function.2,3
The exact cause of IBD is unknown, but it is thought to involve a combination of genes, the immune system and environmental factors.3,4

Uncontrolled UC shows up as inflammation in the large intestine (colon) and rectum, and only affects the innermost lining of these organs. This inflammation can lead to painful sores, such as ulcers, which can then bleed and cause blood in stools (the main symptom of UC).4,5

Explore here how uncontrolled UC may manifest in patients. Learn how this may affect patients’ perception of and treatment expectations for UC. Gain insights into the prevalence and impact of uncontrolled UC and familiarise yourself with tools that were designed to aid in bridging the gap between healthcare professionals and patients to strive for alignment on treatment goals.

Identifying the
unspoken realities behind uncontrolled UC

Uncontrolled UC Loading

Why might patients with UC settle for “OK”?

Why patients settle Loading

The prevalence and impact of uncontrolled UC

Prevalence & impact Loading

Resources to help 
look beyond “OK” for patients’ UC

Resources Loading
References:Lynch WD and Hsu R. Ulcerative Colitis. StatPearls Publishing LLC 2023.Tran S et al. Biochem Soc Trans 2023;51(2):811-826.Fakhoury M et al. J Inflamm Res 2014;7:113-120.Ordás I et al. Lancet 2012;380(9853):1606-1619.Seyedian SS et al. J Med Life 2019;12(2):113-122.

Xeljanz®(tofacitinib citrate) Prescribing information and Inflectra®(infliximab) Prescribing information.

  

PP-UNP-GBR-7049 February 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​